IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2017-06, Vol.35 (S2), p.142-143 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 143 |
|---|---|
| container_issue | S2 |
| container_start_page | 142 |
| container_title | Hematological oncology |
| container_volume | 35 |
| creator | Wang, M.L. Lee, H. Thirumurthi, S. Chuang, H. Hagemeister, F. Westin, J. Fayad, L. Samaniego, F. Turturro, F. Chen, W. Oriabure, O. Feng, L. Zhou, S. Huang, S. Li, S. Zhang, L. Badillo, M. Wu, L. Ahmed, M. Yan, F. Nomie, K. Lam, L. Addison, A. Romaguera, J. |
| description | |
| doi_str_mv | 10.1002/hon.2437_132 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1906625963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1906625963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1922-1e03fdf45f5727f115b16481e45b803d06d32a42b2494b5e68d11c073c7d252f3</originalsourceid><addsrcrecordid>eNp9kctO20AUhkeISg20uz7ASGwxnYuv7Bx7Eo80nmM5YwWvRklsCxAQsEEVuz5Cn6QP1SfpVAGWXZ0jne8__-JD6BslF5QQ9v16_3DBfB5ZytkRmlGSJB4lYXKMZoRFsUcYZ5_RyTTdEuJuJJ6h33JeN0ZqOf_z81ctTXMly3SOF6AUrEWO5y2uRd5kbs0KUYKjZFk2Gkwh6rRqcQZ6BUrmqZGgsdS4hUYvz7EWa9XiXKZLDSuXLlNtlMCZUAqrtqwKKFNcuZTQZnWJN3gtdQ5rDAsMVQW1abQ0LTbw1n-o_4I-DZu7qf_6Nk9RsxAmKzwFS5mlytvRhDGP9oQP3eAHQxCxaKA02NLQj2nvB9uY8I6EHWcbn22Zn_jboA_jjtIdifgu6ljABn6Kzg5_H8f900s_Pdvb_cv44CotTUgYsiAJuaPOD9Ru3E_T2A_2cby534yvlhL7z4h1Ruy7EYcHB_zHzV3_-l_WFqA_cn8BMx6DZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1906625963</pqid></control><display><type>article</type><title>IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO</title><source>Wiley Journals</source><creator>Wang, M.L. ; Lee, H. ; Thirumurthi, S. ; Chuang, H. ; Hagemeister, F. ; Westin, J. ; Fayad, L. ; Samaniego, F. ; Turturro, F. ; Chen, W. ; Oriabure, O. ; Feng, L. ; Zhou, S. ; Huang, S. ; Li, S. ; Zhang, L. ; Badillo, M. ; Wu, L. ; Ahmed, M. ; Yan, F. ; Nomie, K. ; Lam, L. ; Addison, A. ; Romaguera, J.</creator><creatorcontrib>Wang, M.L. ; Lee, H. ; Thirumurthi, S. ; Chuang, H. ; Hagemeister, F. ; Westin, J. ; Fayad, L. ; Samaniego, F. ; Turturro, F. ; Chen, W. ; Oriabure, O. ; Feng, L. ; Zhou, S. ; Huang, S. ; Li, S. ; Zhang, L. ; Badillo, M. ; Wu, L. ; Ahmed, M. ; Yan, F. ; Nomie, K. ; Lam, L. ; Addison, A. ; Romaguera, J.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2437_132</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Consolidation ; Immunotherapy ; Lymphoma ; Mantle ; Mantle cell lymphoma ; Monoclonal antibodies ; Patients ; Rituximab ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2017-06, Vol.35 (S2), p.142-143</ispartof><rights>2017 The Authors. published by John Wiley & Sons, Ltd.</rights><rights>2017 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1922-1e03fdf45f5727f115b16481e45b803d06d32a42b2494b5e68d11c073c7d252f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2437_132$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2437_132$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Wang, M.L.</creatorcontrib><creatorcontrib>Lee, H.</creatorcontrib><creatorcontrib>Thirumurthi, S.</creatorcontrib><creatorcontrib>Chuang, H.</creatorcontrib><creatorcontrib>Hagemeister, F.</creatorcontrib><creatorcontrib>Westin, J.</creatorcontrib><creatorcontrib>Fayad, L.</creatorcontrib><creatorcontrib>Samaniego, F.</creatorcontrib><creatorcontrib>Turturro, F.</creatorcontrib><creatorcontrib>Chen, W.</creatorcontrib><creatorcontrib>Oriabure, O.</creatorcontrib><creatorcontrib>Feng, L.</creatorcontrib><creatorcontrib>Zhou, S.</creatorcontrib><creatorcontrib>Huang, S.</creatorcontrib><creatorcontrib>Li, S.</creatorcontrib><creatorcontrib>Zhang, L.</creatorcontrib><creatorcontrib>Badillo, M.</creatorcontrib><creatorcontrib>Wu, L.</creatorcontrib><creatorcontrib>Ahmed, M.</creatorcontrib><creatorcontrib>Yan, F.</creatorcontrib><creatorcontrib>Nomie, K.</creatorcontrib><creatorcontrib>Lam, L.</creatorcontrib><creatorcontrib>Addison, A.</creatorcontrib><creatorcontrib>Romaguera, J.</creatorcontrib><title>IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO</title><title>Hematological oncology</title><subject>Consolidation</subject><subject>Immunotherapy</subject><subject>Lymphoma</subject><subject>Mantle</subject><subject>Mantle cell lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kctO20AUhkeISg20uz7ASGwxnYuv7Bx7Eo80nmM5YwWvRklsCxAQsEEVuz5Cn6QP1SfpVAGWXZ0jne8__-JD6BslF5QQ9v16_3DBfB5ZytkRmlGSJB4lYXKMZoRFsUcYZ5_RyTTdEuJuJJ6h33JeN0ZqOf_z81ctTXMly3SOF6AUrEWO5y2uRd5kbs0KUYKjZFk2Gkwh6rRqcQZ6BUrmqZGgsdS4hUYvz7EWa9XiXKZLDSuXLlNtlMCZUAqrtqwKKFNcuZTQZnWJN3gtdQ5rDAsMVQW1abQ0LTbw1n-o_4I-DZu7qf_6Nk9RsxAmKzwFS5mlytvRhDGP9oQP3eAHQxCxaKA02NLQj2nvB9uY8I6EHWcbn22Zn_jboA_jjtIdifgu6ljABn6Kzg5_H8f900s_Pdvb_cv44CotTUgYsiAJuaPOD9Ru3E_T2A_2cby534yvlhL7z4h1Ruy7EYcHB_zHzV3_-l_WFqA_cn8BMx6DZg</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Wang, M.L.</creator><creator>Lee, H.</creator><creator>Thirumurthi, S.</creator><creator>Chuang, H.</creator><creator>Hagemeister, F.</creator><creator>Westin, J.</creator><creator>Fayad, L.</creator><creator>Samaniego, F.</creator><creator>Turturro, F.</creator><creator>Chen, W.</creator><creator>Oriabure, O.</creator><creator>Feng, L.</creator><creator>Zhou, S.</creator><creator>Huang, S.</creator><creator>Li, S.</creator><creator>Zhang, L.</creator><creator>Badillo, M.</creator><creator>Wu, L.</creator><creator>Ahmed, M.</creator><creator>Yan, F.</creator><creator>Nomie, K.</creator><creator>Lam, L.</creator><creator>Addison, A.</creator><creator>Romaguera, J.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201706</creationdate><title>IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO</title><author>Wang, M.L. ; Lee, H. ; Thirumurthi, S. ; Chuang, H. ; Hagemeister, F. ; Westin, J. ; Fayad, L. ; Samaniego, F. ; Turturro, F. ; Chen, W. ; Oriabure, O. ; Feng, L. ; Zhou, S. ; Huang, S. ; Li, S. ; Zhang, L. ; Badillo, M. ; Wu, L. ; Ahmed, M. ; Yan, F. ; Nomie, K. ; Lam, L. ; Addison, A. ; Romaguera, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1922-1e03fdf45f5727f115b16481e45b803d06d32a42b2494b5e68d11c073c7d252f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Consolidation</topic><topic>Immunotherapy</topic><topic>Lymphoma</topic><topic>Mantle</topic><topic>Mantle cell lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, M.L.</creatorcontrib><creatorcontrib>Lee, H.</creatorcontrib><creatorcontrib>Thirumurthi, S.</creatorcontrib><creatorcontrib>Chuang, H.</creatorcontrib><creatorcontrib>Hagemeister, F.</creatorcontrib><creatorcontrib>Westin, J.</creatorcontrib><creatorcontrib>Fayad, L.</creatorcontrib><creatorcontrib>Samaniego, F.</creatorcontrib><creatorcontrib>Turturro, F.</creatorcontrib><creatorcontrib>Chen, W.</creatorcontrib><creatorcontrib>Oriabure, O.</creatorcontrib><creatorcontrib>Feng, L.</creatorcontrib><creatorcontrib>Zhou, S.</creatorcontrib><creatorcontrib>Huang, S.</creatorcontrib><creatorcontrib>Li, S.</creatorcontrib><creatorcontrib>Zhang, L.</creatorcontrib><creatorcontrib>Badillo, M.</creatorcontrib><creatorcontrib>Wu, L.</creatorcontrib><creatorcontrib>Ahmed, M.</creatorcontrib><creatorcontrib>Yan, F.</creatorcontrib><creatorcontrib>Nomie, K.</creatorcontrib><creatorcontrib>Lam, L.</creatorcontrib><creatorcontrib>Addison, A.</creatorcontrib><creatorcontrib>Romaguera, J.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, M.L.</au><au>Lee, H.</au><au>Thirumurthi, S.</au><au>Chuang, H.</au><au>Hagemeister, F.</au><au>Westin, J.</au><au>Fayad, L.</au><au>Samaniego, F.</au><au>Turturro, F.</au><au>Chen, W.</au><au>Oriabure, O.</au><au>Feng, L.</au><au>Zhou, S.</au><au>Huang, S.</au><au>Li, S.</au><au>Zhang, L.</au><au>Badillo, M.</au><au>Wu, L.</au><au>Ahmed, M.</au><au>Yan, F.</au><au>Nomie, K.</au><au>Lam, L.</au><au>Addison, A.</au><au>Romaguera, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO</atitle><jtitle>Hematological oncology</jtitle><date>2017-06</date><risdate>2017</risdate><volume>35</volume><issue>S2</issue><spage>142</spage><epage>143</epage><pages>142-143</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.2437_132</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2017-06, Vol.35 (S2), p.142-143 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_1906625963 |
| source | Wiley Journals |
| subjects | Consolidation Immunotherapy Lymphoma Mantle Mantle cell lymphoma Monoclonal antibodies Patients Rituximab Targeted cancer therapy |
| title | IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A01%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IBRUTINIB%E2%80%90RITUXIMAB%20FOLLOWED%20BY%20REDUCED%20CHEMO%E2%80%90IMMUNOTHERAPY%20CONSOLIDATION%20IN%20YOUNG,%20NEWLY%20DIAGNOSED%20MANTLE%20CELL%20LYMPHOMA%20PATIENTS:%20a%20WINDOW%20OF%20OPPORTUNITY%20TO%20REDUCE%20CHEMO&rft.jtitle=Hematological%20oncology&rft.au=Wang,%20M.L.&rft.date=2017-06&rft.volume=35&rft.issue=S2&rft.spage=142&rft.epage=143&rft.pages=142-143&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2437_132&rft_dat=%3Cproquest_cross%3E1906625963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1906625963&rft_id=info:pmid/&rfr_iscdi=true |